Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Importance

Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown.

Objective

To compare precision medicine data and outcomes between Black and White men with mCRPC.

Design, setting, and participants

This retrospective cohort study used data collected by the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, a multi-institutional registry with linked clinicogenomic data, from April 2020 to December 2021. Participants included Black and White patients with mCRPC with molecular data. Data were analyzed from December 2021 to May 2023.

Exposures

Database-reported race and ethnicity

SUBMITTER: Hwang C 

PROVIDER: S-EPMC10507489 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature